Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.
Arthritis Knee Pain Centers
2 followers
Harrison.ai
3 followers
AstraZeneca
425 followers
Bayer
342 followers
Bristol-Myers Squibb
260 followers
UCB
49 followers
Astellas Pharma
42 followers
NYU Langone Health
27 followers
Tilray
19 followers
Perrigo
16 followers
West Pharmaceutical Services
8 followers
Explore companies